Under Dr. David Siegel, an internationally recognized leader in the field, the Multiple Myeloma Division at Hackensack Meridian Health’s John Theurer Cancer Center (JTCC) is home to one of the world’s largest cohorts of patients (more than 2,000) with multiple myeloma on active therapy. In partnership with major developers of drug therapies for myeloma, Dr. Siegel and his team have brought breakthrough treatments to their patients for decades. Milestones in the program include:
More than 250 stem cell transplants for multiple myeloma patients performed per year
Unique capacity to assume primary oncological and tertiary/quaternary sub- specialized care; No other multiple myeloma referral center can duplicate this level of access to patients
Research hub for Regional Cancer Care Associates (RCCA)
Member of the Multiple Myeloma Research Consortium (MMRC) and Tissue Bank, integrating myeloma tissue samples with corresponding genomic and clinical data to enable researchers to rapidly advance research efforts
Second largest enroller of patients in COMMpass study, the Multiple Myeloma Research Foundation’s (MMRF) Personalized Medicine Initiative, built on new genome sequencing technologies discovered by JTCC and other leading research institutions
Principle investor in Cancer Outcomes Tracking and Analysis (COTA), Inc. to improve clinical outcomes and reduce costs (value-based care) through sophisticated data analytics
Unprecedented partnership with Memorial Sloan Kettering Cancer Center
Established Georgetown Lombardi Cancer Center bone marrow transplant program
Over 300 new plasma cell dyscrasia cases treated per year
Involved in the development of all newly-approved multiple myeloma drugs for the last 10 years